Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

Vanderbilt Researchers Identify Protein's Possible Role in Chemotherapy Resistance

David Cortez, Ph.D.

Researchers at Vanderbilt University Medical Center (VUMC) have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have mutations in the tumor suppressor gene BRCA2.

The protein, RADX, is a DNA-binding protein. It regulates the activity of an enzyme called RAD51, which helps repair tumor-promoting DNA breaks and ensure an accurate copy of the DNA is made during cell division. RAD51, in turn, is gathered up and transported to the sites of DNA damage and DNA replication by the BRCA2 protein.

Mutations in the BRCA2 gene disrupt the DNA repair and replication functions of the BRCA2/RAD51 pathway, increasing the risk of cancers of the breast, ovaries, prostate and pancreas as well as melanoma.

Since BRCA2 mutations also reduce the ability of tumor cells to repair broken DNA, these cells are sensitive to DNA-damaging anti-cancer drugs like cisplatin and newly approved DNA repair inhibitors like Olaparib. If the cells acquire secondary mutations that restore normal BRCA2 function, however, they can become resistant to the drugs.

This is the case with ovarian cancer. Within six months one quarter of ovarian tumors will become resistant to cisplatin. Only a third of patients survive beyond five years, making ovarian cancer the fifth-leading cause of cancer death among women in the United States.

RADX, the protein discovered by the Vanderbilt scientists, may be a key to understanding and overcoming this resistance.

In a paper published in the journal Molecular Cell, David Cortez, Ph.D., and colleagues describe how RADX regulates the activity of RAD51 in a way that promotes genome stability and modulates drug sensitivity.

Much remains to be learned. But if, as suspected, RADX determines how tumors respond to therapy, it could be a target for efforts to overcome resistance, the researchers concluded.

The paper's first authors were Huzefa Dungrawala, Ph.D., a postdoctoral fellow in Cortez's lab, and graduate student Kamakoti Bhat. Cortez is Ingram Professor of Cancer Research and professor of Biochemistry and co-leader of the Genome Maintenance Program in the Vanderbilt-Ingram Cancer Center.

The research was supported in part by National Institutes of Health grants GM116616, CA092584, CA212435 and GM118089.


Related Articles:

Recent Articles

Bipartisan Group of Senate Health Committee Members Introduce Bill to Spur Development of New Non-Addictive Painkiller

Read More

There's a New Bipartisan Budget & Most Healthcare Organizations are Happy

Read More

AHA Supportive of Bill Addressing Community Rights to Set Smoking Policy

Preemption Repeal a Breath of Fresh Air for Tennessee: The fate of local smoking ordinances impacting the secondhand smoke Tennesseans breathe may finally be given to communities at the local level. Municipalities throughout Tennessee would be allowed to craft their own local smoking policies protecting the health of citizens through a bill making its way through the Tennessee Legislature.

Read More

Healthcare Collaboration

Key healthcare associations and payer organizations look to simplify the pre-authorization process with a recently released consensus statement outlining key areas for improvement.

Read More

The Battle over 340B

The battle over 340B continues as hospitals serving some of the nation's most vulnerable patients worry what will happen if $1.6 billion in cuts go through.

Read More

Position on Governor Haslam's TN Together Initiative

The Tennessee Medical Association Board of Trustees has adopted the following position on Governor Haslam's TN Together plan for addressing the state's opioid abuse epidemic.

Read More

Doctors Aim for Another Big Year on Capitol Hill

With the 2018 legislative session in full swing, TMA is ready to advocate on behalf of its more than 9,000 physician members.

Read More

DOJ Signals New Approach to Frivolous Qui Tam Actions

The Department of Justice recently signaled a possible move toward dismissing more qui tam cases deemed to be meritless.

Read More

Wall Street Weighs In for 2018

Top Wall Street analysts shared their industry predictions for 2018 at the Nashville Health Care Council signature event.

Read More

The Impact of Clinical Trials in Tennessee

With nearly 1,000 clinical trials in the state, a new study finds biopharma research supports 52,000 jobs in Tennessee and ads $11.7 billion to the economy.

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: